Related Experiment Videos
Amethocaine-induced inhibition of mitochondrial monoamine oxidase activity
Abstract:
Amethocaine (tetracaine) (1-10 microM) produces a concentration-dependent in-vitro inhibition of mitochondrial membrane-bound MAO activity towards tyramine (18-84% in brain and 19-84% in liver) and 5-hydroxytryptamine (5-HT) (23-94% in brain and 20-100% in liver). At relatively higher concentrations (25-300 microM) of amethocaine, benzylamine oxidation is inhibited in brain (24-91%) and liver (29-100%). The extent of MAO inhibition is appreciably reduced when preincubation time of the enzyme with a low concentration (7.5 microM) of amethocaine is increased from zero to 45 min. This inhibition is reversible. The Km of MAO for tyramine is increased in brain (106-473%) and liver (121-352%) in the presence of amethocaine (2-7.5 microM) accompanied by a decrease in Vmax (21-51% in brain and 18-57% in liver). Similarly the Km of MAO for 5-HT is increased to the extent of 79-336% in brain and 51-225% in liver and the corresponding Vmax is decreased by 35-55% and 39-74%, respectively, in the presence of 2-5 microM amethocaine. At relatively higher concentrations (25-100 microM), amethocaine increases the Km of MAO for benzylamine in brain (25-101%) and liver (26-85%) and decreases the Vmax by 28-64% and 32-63% in the respective tissues. Thus these results suggest that amethocaine preferentially inhibits MAO-A and the nature of inhibition is reversible and of mixed type.
Insights
Amethocaine (tetracaine) reversibly inhibits monoamine oxidase (MAO) enzymes, particularly MAO-A, in brain and liver tissues. This mixed-type inhibition affects the oxidation of tyramine, 5-hydroxytryptamine, and benzylamine.
Area of Science:
- Biochemistry
- Pharmacology
- Enzymology
Background:
- Mitochondrial membrane-bound monoamine oxidase (MAO) enzymes are crucial for neurotransmitter metabolism.
- Amethocaine (tetracaine) is a local anesthetic with potential interactions with biological systems.
- Understanding MAO inhibition by amethocaine is important for its pharmacological profile.
Purpose of the Study:
- To investigate the in-vitro inhibitory effects of amethocaine on MAO activity.
- To determine the substrate specificity and kinetic parameters of amethocaine-induced MAO inhibition.
- To elucidate the type and reversibility of MAO inhibition by amethocaine.
Main Methods:
- In-vitro enzyme assays measuring MAO activity towards tyramine, 5-hydroxytryptamine (5-HT), and benzylamine.
- Concentration-dependent inhibition studies.
- Kinetic analysis (Km and Vmax determination) and preincubation time experiments.
Main Results:
- Amethocaine exhibited concentration-dependent inhibition of MAO activity towards tyramine, 5-HT, and benzylamine in both brain and liver.
- Inhibition was reversible and characterized as mixed-type, with increased Km and decreased Vmax for all substrates.
- Amethocaine preferentially inhibited MAO-A, as indicated by its effects on tyramine and 5-HT oxidation.
Conclusions:
- Amethocaine acts as a reversible, mixed-type inhibitor of MAO.
- The drug demonstrates preferential inhibition of MAO-A.
- These findings contribute to understanding the biochemical interactions of amethocaine.